Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.

Management raised full-year guidance after returning to organic growth in distribution.

BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.

DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.

Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.

Avantor, Inc. reported past second-quarter 2026 results showing sales of US$1,692.3 million, slightly above a year earlier, while net income and earnings per share from continuing operations declined versus the prior-year period. Despite softer profitability under GAAP, Avantor’s adjusted earnings and revenue exceeded analyst expectations, and management raised full-year sales and earnings guidance on better-than-expected organic growth in its VWR segment. With raised full-year guidance...

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Life sciences company Avantor (NYSE:AVTR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $1.69 billion. Its non-GAAP profit of $0.21 per share was 11% above analysts’ consensus estimates.

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

AVTR tops Q2 earnings and revenue estimates as VWR returned to organic growth early, prompting higher 2026 revenues and earnings guidance.

Moby summary of Avantor, Inc.'s Q2 2026 earnings call

Avantor (NYSE:AVTR) reported second-quarter 2026 results that exceeded its expectations on several measures, supported by a return to organic growth in its VWR Distribution & Services segment, strong free cash flow and progress under its Revival operational improvement program. Revenue totaled

Avantor Inc (AVTR) raises 2026 guidance amid strong VWR segment performance and strategic debt reduction.

The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Avantor (AVTR) delivered earnings and revenue surprises of +10.53% and +4.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Life sciences company Avantor (NYSE:AVTR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $1.69 billion. Its non-GAAP profit of $0.21 per share was 11% above analysts’ consensus estimates.

Life sciences company Avantor (NYSE:AVTR) will be reporting results this Wednesday before market hours. Here’s what investors should know.

How Avantor’s NuSil collaboration ties into the stock story Avantor (AVTR) drew investor attention after announcing an expanded collaboration between its NuSil brand and the Population Council, supporting development of a three-month dapivirine vaginal ring for HIV prevention using high-purity medical-grade silicones. The project builds on NuSil’s prior work supplying silicones for an approved one-month ring used across several sub-Saharan African markets. It now moves into regulatory review...

Avantor (NYSE:AVTR), through its NuSil brand, has expanded its collaboration with the Population Council. The partnership focuses on supporting the development of a three-month dapivirine vaginal ring for HIV prevention. The product is aimed at improving HIV prevention options for women, particularly in regions with higher prevalence. Avantor, a supplier of materials and solutions to the life sciences and advanced technologies sectors, is deepening its role in global health through this...

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) delivered earnings and revenue surprises of +4.17% and +1.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Avantor (AVTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVTR vs. ICLR: Which Stock Is the Better Value Option?

DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Avantor (AVTR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AVTR's shares jump nearly 7% as NuSil expands its HIV prevention partnership for a three-month dapivirine vaginal ring.

Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here. The letter states that the portfolio holdings are attractive now based on both P/V and P/FCF metrics. However, the Fund returned 3.87% in the quarter, significantly lagging the S&P 500’s […]